| Schedule of Disaggregation of Revenue |
The following table presents a summary of total revenues (in thousands): | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | 2025 | | 2024 | | 2023 | | Xywav | $ | 1,656,986 | | | $ | 1,473,202 | | | $ | 1,272,977 | | | Xyrem | 146,034 | | | 233,816 | | | 569,730 | | | | | | | | | Epidiolex/Epidyolex | 1,059,197 | | | 972,423 | | | 845,468 | | Sativex1 | 16,277 | | | 18,877 | | | 19,668 | | | | | | | | | Total Neuroscience | 2,878,494 | | | 2,698,318 | | | 2,707,843 | | | Rylaze/Enrylaze | 402,920 | | | 410,846 | | | 394,226 | | | Zepzelca | 307,309 | | | 320,318 | | | 289,533 | | | Defitelio/defibrotide | 199,392 | | | 216,565 | | | 184,000 | | | Vyxeos | 146,709 | | | 162,595 | | | 147,495 | | | Modeyso | 48,043 | | | — | | | — | | | Ziihera | 24,810 | | | 1,051 | | | — | | | Total Oncology | 1,129,183 | | | 1,111,375 | | | 1,015,254 | | | Other | 14,172 | | | 11,471 | | | 13,846 | | | Product sales, net | 4,021,849 | | | 3,821,164 | | | 3,736,943 | | | High-sodium oxybate AG royalty revenue | 211,725 | | | 217,575 | | | 75,918 | | | Other royalty and contract revenues | 34,012 | | | 30,211 | | | 21,343 | | | Total revenues | $ | 4,267,586 | | | $ | 4,068,950 | | | $ | 3,834,204 | | ____________________________(1) Divestiture of Sativex was completed in October 2025. The following table presents a summary of total revenues attributed to geographic sources (in thousands): | | | | | | | | | | | | | | | | | | | Year Ended December 31, | | 2025 | | 2024 | | 2023 | | United States | $ | 3,831,598 | | | $ | 3,660,109 | | | $ | 3,489,977 | | | Europe | 341,122 | | | 312,706 | | | 269,243 | | | All other | 94,866 | | | 96,135 | | | 74,984 | | | Total revenues | $ | 4,267,586 | | | $ | 4,068,950 | | | $ | 3,834,204 | |
|